[Cytomegalovirus infection following lung transplantation].
The significance of cytomegalovirus (CMV) infection after lung transplantation was investigated in 20 patients (ten women and ten men; mean age 46 [21-67] years). Indications for transplantation were emphysema (n = 6), cystic fibrosis (n = 2), primary pulmonary hypertension (n = 2), pulmonary fibrosis (n = 5), obliterating bronchiolitis (n = 2), cystic lung (n = 2) and bronchiectasis (n = 1). Incidence, diagnostic parameters (serology, virus isolation and histology) and efficacy of prophylactic and therapeutic measures were recorded. 16 of the 20 patients developed a CMV infection, which in 12 was clinically significant. CMV pneumonia developed in two patients, proving fatal in one. The infection occurred a median of 47 (17-200) days after the transplantation. Administration of Ganciclovir (5 mg/kg twice daily intravenously) brought about remission of symptoms in all but one of the patients and improved the clinical parameters.--This experience demonstrates that regular monitoring of the patients for possible CMV infection and its early therapy can achieve a low death rate.
Schmuth
M
M
II. Chirurgische Universitätsklinik, Wien.
End
A
A
Grimm
M
M
Ringel
H
H
Wisser
W
W
Wieselthaler
G
G
Wollenek
G
G
Klepetko
W
W
D000328:Adult; D000368:Aged; D003168:Complement Fixation Tests; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged
D007166:Immunosuppressive Agents; D015774:Ganciclovir